Clinical Trial Update: Prevention of Contrast Induced Nephropathy by Erythropoietin [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating whether erythropoietin can prevent contrast-induced nephropathy in patients with diabetes and chronic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Diabetes Mellitus

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Western Galilee Hospital-Nahariya | Conditions: Diabetes, Chronic Kidney Insufficiency | Phase 3 | Status: UNKNOWN